CERVOMED INC (CRVO)
US15713L1098 - Common Stock
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...
CRVO Stock Earnings: CervoMed Beats EPS, Beats Revenue for Q2 2024
CRVO stock results show that CervoMed beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- Completed enrollment in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We have all of the biggest pre-market stock movers that traders are going to want to read about on Tuesday!
CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...
CervoMed to Participate in the Emerging Growth Conference
BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data expected in December 2024 ...
CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q4 2023
CRVO stock results show that CervoMed missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
Low priced stocks to buy for growth provide great value to investors in the $20 range and are expected to pop before 2025.
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with...
CervoMed Becomes Oversold (CRVO)
CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q1 2024
CRVO stock results show that CervoMed missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy...
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and...
CervoMed to Participate in Upcoming Investor Conferences
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront...
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Neflamapimod effects on...
CervoMed to Participate in the BIO CEO and Investor Conference
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative...
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
-Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results,...
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB...
CervoMed to Participate in the Emerging Growth Conference 66
BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative...
CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference
/PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced...
CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference
/PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday!
CervoMed shares soar following merger, reverse stock split (NASDAQ:CRVO)
Shares of CervoMed (CRVO) soared Thursday during their first day of trading in the wake of a merger between Diffuse Pharmaceuticals (DFFN) and EIP Pharma and a reverse stock split.
CervoMed Announces Completion of Merger with EIP Pharma
/PRNewswire/ -- CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) (NASDAQ: CRVO), now a clinical-stage company focused on developing treatments...